110 related articles for article (PubMed ID: 15006399)
1. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.
Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J
Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399
[TBL] [Abstract][Full Text] [Related]
2. New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.
Renner S; Ludwig V; Boden O; Scheffer U; Göbel M; Schneider G
Chembiochem; 2005 Jun; 6(6):1119-25. PubMed ID: 15883975
[TBL] [Abstract][Full Text] [Related]
3. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association.
Zeng L; Li J; Muller M; Yan S; Mujtaba S; Pan C; Wang Z; Zhou MM
J Am Chem Soc; 2005 Mar; 127(8):2376-7. PubMed ID: 15724976
[TBL] [Abstract][Full Text] [Related]
4. Alpha,alpha-trehalose derivatives bearing guanidino groups as inhibitors to HIV-1 Tat-TAR RNA interaction in human cells.
Wang M; Xu Z; Tu P; Yu X; Xiao S; Yang M
Bioorg Med Chem Lett; 2004 May; 14(10):2585-8. PubMed ID: 15109657
[TBL] [Abstract][Full Text] [Related]
5. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.
Hamy F; Brondani V; Flörsheimer A; Stark W; Blommers MJ; Klimkait T
Biochemistry; 1998 Apr; 37(15):5086-95. PubMed ID: 9548739
[TBL] [Abstract][Full Text] [Related]
6. Amino disaccharides having an alpha-(1-->4) or a beta-(1-->4) linkage, their synthesis and evaluation as a potential inhibitor for HIV-1 TAR-Tat.
Iguchi T; Ishikawa H; Matumoto H; Mizuno M; Goto K; Hamasaki K
Nucleic Acids Symp Ser (Oxf); 2005; (49):169-70. PubMed ID: 17150687
[TBL] [Abstract][Full Text] [Related]
7. Design and SAR of new substituted purines bearing aryl groups at N9 position as HIV-1 Tat-TAR interaction inhibitors.
Pang R; Zhang C; Yuan D; Yang M
Bioorg Med Chem; 2008 Sep; 16(17):8178-86. PubMed ID: 18693018
[TBL] [Abstract][Full Text] [Related]
8. Recent status of HIV-1 gene expression inhibitors.
Baba M
Antiviral Res; 2006 Sep; 71(2-3):301-6. PubMed ID: 16488488
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
Chen S; Chen R; He M; Pang R; Tan Z; Yang M
Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
[TBL] [Abstract][Full Text] [Related]
10. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA.
Murchie AI; Davis B; Isel C; Afshar M; Drysdale MJ; Bower J; Potter AJ; Starkey ID; Swarbrick TM; Mirza S; Prescott CD; Vaglio P; Aboul-ela F; Karn J
J Mol Biol; 2004 Feb; 336(3):625-38. PubMed ID: 15095977
[TBL] [Abstract][Full Text] [Related]
11. Anti-Tat and anti-HIV activities of trimers of n-alkylglycines.
Márquez N; Sancho R; Macho A; Moure A; Masip I; Messeguer A; Muñoz E
Biochem Pharmacol; 2006 Feb; 71(5):596-604. PubMed ID: 16405868
[TBL] [Abstract][Full Text] [Related]
12. An allosteric drug, o,o'-bismyristoyl thiamine disulfide, suppresses HIV-1 replication through prevention of nuclear translocation of both HIV-1 Tat and NF-kappa B.
Shoji S; Furuishi K; Ogata A; Yamataka K; Tachibana K; Mukai R; Uda A; Harano K; Matsushita S; Misumi S
Biochem Biophys Res Commun; 1998 Aug; 249(3):745-53. PubMed ID: 9731208
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibition of HIV-1 gene expression and TAT-mediated apoptosis in human T cells by novel mono- and multitarget anti-TAT/Rev/Env ribozymes and a general purpose RNA-cleaving DNA-enzyme.
Unwalla H; Chakraborti S; Sood V; Gupta N; Banerjea AC
Antiviral Res; 2006 Nov; 72(2):134-44. PubMed ID: 16790281
[TBL] [Abstract][Full Text] [Related]
14. The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.
Rayne F; Vendeville A; Bonhoure A; Beaumelle B
J Virol; 2004 Nov; 78(21):12054-7. PubMed ID: 15479845
[TBL] [Abstract][Full Text] [Related]
15. The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors.
Yuan D; He M; Pang R; Lin SS; Li Z; Yang M
Bioorg Med Chem; 2007 Jan; 15(1):265-72. PubMed ID: 17055732
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: squaryldiamide as a new potential bioisostere of unsubstituted guanidine.
Lee CW; Cao H; Ichiyama K; Rana TM
Bioorg Med Chem Lett; 2005 Oct; 15(19):4243-6. PubMed ID: 16054360
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel beta-carboline derivatives as Tat-TAR interaction inhibitors.
Yu X; Lin W; Li J; Yang M
Bioorg Med Chem Lett; 2004 Jun; 14(12):3127-30. PubMed ID: 15149658
[TBL] [Abstract][Full Text] [Related]
18. 2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction.
Gatto B; Tabarrini O; Massari S; Giaretta G; Sabatini S; Del Vecchio C; Parolin C; Fravolini A; Palumbo M; Cecchetti V
ChemMedChem; 2009 Jun; 4(6):935-8. PubMed ID: 19283692
[TBL] [Abstract][Full Text] [Related]
19. 4-Phenylcoumarins as HIV transcription inhibitors.
Bedoya LM; Beltrán M; Sancho R; Olmedo DA; Sánchez-Palomino S; del Olmo E; López-Pérez JL; Muñoz E; San Feliciano A; Alcamí J
Bioorg Med Chem Lett; 2005 Oct; 15(20):4447-50. PubMed ID: 16137881
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and assay of isoquinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
He M; Yuan D; Lin W; Pang R; Yu X; Yang M
Bioorg Med Chem Lett; 2005 Sep; 15(17):3978-81. PubMed ID: 16039124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
